Jacobi Capital Management LLC Has $684,000 Stake in AstraZeneca PLC $AZN

Jacobi Capital Management LLC decreased its position in AstraZeneca PLC (NASDAQ:AZN) by 7.5% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 9,301 shares of the company’s stock after selling 759 shares during the quarter. Jacobi Capital Management LLC’s holdings in AstraZeneca were worth $684,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Goldman Sachs Group Inc. grew its position in AstraZeneca by 30.9% during the first quarter. Goldman Sachs Group Inc. now owns 13,647,948 shares of the company’s stock worth $1,003,124,000 after buying an additional 3,224,251 shares in the last quarter. Boston Partners grew its position in AstraZeneca by 35.9% during the first quarter. Boston Partners now owns 5,036,645 shares of the company’s stock worth $368,712,000 after buying an additional 1,329,166 shares in the last quarter. Ameriprise Financial Inc. grew its position in AstraZeneca by 5.6% during the first quarter. Ameriprise Financial Inc. now owns 4,942,367 shares of the company’s stock worth $364,283,000 after buying an additional 261,064 shares in the last quarter. WCM Investment Management LLC grew its position in AstraZeneca by 7.3% during the first quarter. WCM Investment Management LLC now owns 4,003,070 shares of the company’s stock worth $295,387,000 after buying an additional 272,537 shares in the last quarter. Finally, Invesco Ltd. grew its position in AstraZeneca by 33.2% during the first quarter. Invesco Ltd. now owns 3,807,522 shares of the company’s stock worth $279,853,000 after buying an additional 948,659 shares in the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

Analyst Ratings Changes

Separately, Berenberg Bank set a $97.00 price target on AstraZeneca in a research report on Wednesday, July 9th. Three research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $86.00.

AstraZeneca Trading Down 1.9%

Shares of AZN stock opened at $79.56 on Friday. The stock’s fifty day moving average price is $75.95 and its two-hundred day moving average price is $72.97. The company has a market cap of $246.74 billion, a PE ratio of 29.91, a P/E/G ratio of 1.49 and a beta of 0.37. AstraZeneca PLC has a fifty-two week low of $61.24 and a fifty-two week high of $82.41. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.67 and a current ratio of 0.86.

AstraZeneca (NASDAQ:AZN) last issued its earnings results on Tuesday, July 29th. The company reported $1.09 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.09. The firm had revenue of $14.46 billion for the quarter, compared to the consensus estimate of $14.08 billion. AstraZeneca had a return on equity of 32.84% and a net margin of 14.68%.The company’s revenue was up 16.1% compared to the same quarter last year. During the same quarter last year, the business posted $1.24 EPS. Equities analysts predict that AstraZeneca PLC will post 4.51 EPS for the current fiscal year.

AstraZeneca Cuts Dividend

The firm also recently announced a semi-annual dividend, which was paid on Monday, September 8th. Shareholders of record on Friday, August 8th were issued a $0.505 dividend. This represents a dividend yield of 200.0%. The ex-dividend date of this dividend was Friday, August 8th. AstraZeneca’s dividend payout ratio (DPR) is currently 37.97%.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.